AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24055415 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Gy in 15 fractions over 3 weeks
Number of subjects: 4441
Study 20935692 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac (n = 9)
Number of subjects: 37
Study 20935692 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac (n = 11)
Number of subjects: 37
Study 20935692 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac (n = 8)
Number of subjects: 37
Study 20935692 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac (n = 9)
Number of subjects: 37
Study 20935692 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac
Number of subjects: 37
Study 20935692 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac
Number of subjects: 37
Study 17785764 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab 6 mg/kg every 2 weeks
Number of subjects: 176
Study 17785764 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 176
Study 16843157 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise rotational osteotomy and fixation of the ulna followed by the radius
Number of subjects: 10
Study 16843157 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating the radius followed by the ulna
Number of subjects: 10
Study 16843157 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotating the radius alone
Number of subjects: 10
Study 16843157 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulna osteotomy alone
Number of subjects: 10
Study 12970516 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil 5 mg/d
Number of subjects: 603
Study 12970516 — intervention group
Group type: EXPERIMENTAL
Intervention: donepezil 10 mg/d
Number of subjects: 603
Study 12970516 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 603
Study 10994000 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-l-carnitine (ALCAR) 1 g tid
Number of subjects: 229
Study 10994000 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study 8778893 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiment 1 (intercepting a moving spot on a computer screen)
Number of subjects: 51
Study 8778893 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiment 2 (intercepting a moving table tennis ball)
Number of subjects: 51
Study 8778893 — intervention group
Group type: EXPERIMENTAL
Intervention: Experiment 3 (hitting a ball to reach a moving human target)
Number of subjects: 51
Study 1814984 — intervention group
Group type: EXPERIMENTAL
Intervention: Marco MT‐336 automated perimeter
Number of subjects: 0
Study 1814984 — intervention group
Group type: COMPARATOR
Intervention: Goldmann‐type manual kinetic perimetry
Number of subjects: 0
Study 6303209 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefmenoxime (1.0 g)
Number of subjects: 121
Study 6303209 — intervention group
Group type: COMPARATOR
Intervention: Procaine penicillin G (4.8 X 10(6) U) + probenecid (1.0 g orally)
Number of subjects: 121
Study 31801620 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg
Number of subjects: 712
Study 31801620 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 150 mg
Number of subjects: 712
Study 31801620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 712
Study 31801620 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 300 mg and 150 mg
Number of subjects: 712
Study 30235387 — intervention group
Group type: EXPERIMENTAL
Intervention: Sarecycline 1.5 mg/kg/day
Number of subjects: 2000
Study 30235387 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2000
Study 28586585 — intervention group
Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA)
Number of subjects: 60
Study 28586585 — intervention group
Group type: COMPARATOR
Intervention: General Anaesthesia (GA)
Number of subjects: 60
Study 28586585 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 60
Study 24569263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 670
Study 24569263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 50 mg twice daily
Number of subjects: 670
Study 24569263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 140 mg once daily
Number of subjects: 670
Study 24569263 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 70 mg twice daily
Number of subjects: 670
Study 22353558 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Activity Scale for the Elderly (PASE)
Number of subjects: 40
Study 22353558 — intervention group
Group type: COMPARATOR
Intervention: Actigraph GT1M accelerometer
Number of subjects: 40
Study 22353558 — intervention group
Group type: COMPARATOR
Intervention: International Physical Activity Questionnaire (IPAQ)
Number of subjects: 40
Study 21455450 — intervention group
Group type: EXPERIMENTAL
Intervention: Agnikarma (cauterization treatment)
Number of subjects: 40
Study 21455450 — intervention group
Group type: COMPARATOR
Intervention: Katibasti
Number of subjects: 40
Study 17878472 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 0
Study 17878472 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 16351563 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine supplementation
Number of subjects: 7
Study 12409756 — intervention group
Group type: EXPERIMENTAL
Intervention: Customized pharyngeal flap
Number of subjects: 50
Study 12409756 — intervention group
Group type: COMPARATOR
Intervention: Sphincter pharyngoplasty
Number of subjects: 50
Study 10467966 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 239
Study 10467966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 7880187 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (15 mg/day for 1 month, tapered thereafter)
Number of subjects: 56
Study 7880187 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 56
Study 2120362 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional mandibular block injection technique
Number of subjects: 200
Study 2120362 — intervention group
Group type: COMPARATOR
Intervention: Closed-mouth mandibular block injection technique
Number of subjects: 200
Study 2120362 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 200
Study 232043 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 31144389 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk of shift work disorder
Number of subjects: 202
Study 31144389 — intervention group
Group type: EXPERIMENTAL
Intervention: Shift work disorder, number of night shifts, and alcoholic drinks on non-work days
Number of subjects: 202
Study 31144389 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression and years of shift work
Number of subjects: 202
Study 30395687 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline vertebral fractures (VF) detected by lateral spine imaging (LSI)
Number of subjects: 1084
Study 31473729 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% cetylpyridinium chloride
Number of subjects: 40
Study 31473729 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine
Number of subjects: 40
Study 31473729 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempered rinses at 47ºC
Number of subjects: 40
Study 25497165 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical tissue removal system (TRUCLEAR 5.0 System)
Number of subjects: 133
Study 25497165 — intervention group
Group type: COMPARATOR
Intervention: Bipolar electrosurgery system (GYNECARE VERSAPOINT)
Number of subjects: 133
Study 23375406 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (1 mg twice daily)
Number of subjects: 40
Study 23375406 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 40
Study 21991733 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 microg/kg in 20 mL saline
Number of subjects: 54
Study 21991733 — intervention group
Group type: COMPARATOR
Intervention: Placebo solution 20 mL
Number of subjects: 54
Study 19863364 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program 'Living Well with COPD' including a written action plan and case manager support
Number of subjects: 166
Study 19863364 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 166
Study 17098576 — intervention group
Group type: EXPERIMENTAL
Intervention: Green ink
Number of subjects: 2524
Study 17098576 — intervention group
Group type: COMPARATOR
Intervention: Black ink
Number of subjects: 2524
Study 17098576 — intervention group
Group type: COMPARATOR
Intervention: Brown envelope
Number of subjects: 2524
Study 17098576 — intervention group
Group type: EXPERIMENTAL
Intervention: White envelope
Number of subjects: 2524
Study 15388819 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal protein diet (NPD) (1.20+/‐0.06 g/kg/day)
Number of subjects: 7
Study 15388819 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) (0.66+/‐0.04 g/kg/day)
Number of subjects: 7
Study 15388819 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 7
Study 11352441 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150mg twice daily during a 3‐day pretreatment phase and 1 tablet of ranitidine with a single 400mg dose of moxifloxacin
Number of subjects: 24
Study 11352441 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox 70 10ml given simultaneously with moxifloxacin
Number of subjects: 24
Study 11352441 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox 70 10ml given 4 hours before moxifloxacin
Number of subjects: 24
Study 11352441 — intervention group
Group type: EXPERIMENTAL
Intervention: Maalox 70 10ml given 2 hours after moxifloxacin
Number of subjects: 24
Study 11352441 — intervention group
Group type: COMPARATOR
Intervention: moxifloxacin alone
Number of subjects: 24
Study 9398108 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol (15 mg/day)
Number of subjects: 20
Study 7957347 — intervention group
Group type: EXPERIMENTAL
Intervention: N‐isopropyl‐p‐[123I]iodoamphetamine (IMP) SPECT
Number of subjects: 5
Study 7957347 — intervention group
Group type: COMPARATOR
Intervention: Age-matched normal controls
Number of subjects: 5
Study 3297719 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy with Vincristine, Cyclophosphamide, and Prednisone after regional radiotherapy in stage I
Number of subjects: 468
Study 3297719 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdiaphragmatic irradiation after regional radiotherapy in stage II
Number of subjects: 468
Study 3297719 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 courses of chemotherapy with Adriamycin, VM26, Cyclophosphamide, and Prednisone in stage III and IV
Number of subjects: 468
Study 3297719 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular lymphoma in stage III and IV
Number of subjects: 468
Study 3297719 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage IV disease due to bone marrow involvement
Number of subjects: 468
Study 29054720 — intervention group
Group type: EXPERIMENTAL
Intervention: da Vinci Surgical Skills Simulator (dVSSS)
Number of subjects: 39
Study 26729347 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive-resisted exercise (PRE) intervention conducted twice weekly for 12 weeks
Number of subjects: 160
Study 26729347 — intervention group
Group type: COMPARATOR
Intervention: Usual daily activities (Control group)
Number of subjects: 160
Study 25472808 — intervention group
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane block with ropivacaine 0.375% plus postoperative patient-controlled intravenous analgesia with morphine (TAP group, n = 50)
Number of subjects: 125
Study 25472808 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative intravenous lidocaine plus postoperative patient-controlled intravenous analgesia with morphine (LIDO group, n = 50)
Number of subjects: 125
Study 25472808 — intervention group
Group type: COMPARATOR
Intervention: Postoperative patient-controlled intravenous analgesia with morphine (control group, n = 25)
Number of subjects: 125
Study 22137366 — intervention group
Group type: EXPERIMENTAL
Intervention: Student Bodies™+ (SB+) intervention
Number of subjects: 126
Study 22137366 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 126
Study 20467151 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin or Atorvastatin
Number of subjects: 252
Study 18936764 — intervention group
Group type: EXPERIMENTAL
Intervention: DAG oil (10 g day(-1))
Number of subjects: 14
Study 18936764 — intervention group
Group type: COMPARATOR
Intervention: TAG oil (10 g day(-1))
Number of subjects: 14
Study 16424987 — intervention group
Group type: EXPERIMENTAL
Intervention: Rendezvous technique (videolaparoscopic cholecystectomy, intraoperative cholangiography, and EST during the surgical procedure)
Number of subjects: 256
Study 16424987 — intervention group
Group type: COMPARATOR
Intervention: Traditional method of bile duct cannulation (preoperative ERCP and EST)
Number of subjects: 256
Study 14604931 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 hour training programme promoting an obesity management model
Number of subjects: 843
Study 14604931 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training programme)
Number of subjects: 843
Study 11044160 — intervention group
Group type: COMPARATOR
Intervention: Stapled haemorrhoidectomy
Number of subjects: 40
Study 11044160 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutured haemorrhoidectomy
Number of subjects: 40
Study 8723457 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 400 mg i.v. every 8 h
Number of subjects: 8
Study 8723457 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 400 mg i.v. every 12 h
Number of subjects: 8
Study 1401997 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-gamma
Number of subjects: 14
Study 1401997 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 14
Study 3834009 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery with temporary AV-fistula
Number of subjects: 120
Study 3834009 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 120
Study 3834009 — intervention group
Group type: EXPERIMENTAL
Intervention: PTFE graft with AV-fistula
Number of subjects: 120
Study 30226339 — intervention group
Group type: EXPERIMENTAL
Intervention: EVE group: 5 mg of 0.5% isobaric bupivacaine plus 15 Âµg of fentanyl injection followed by 10 mL of sterile saline injection.
Number of subjects: 50
Study 30226339 — intervention group
Group type: COMPARATOR
Intervention: Control group: 10 mg of 0.5% isobaric bupivacaine plus 15 Âµg of fentanyl injection.
Number of subjects: 50
Study 30226339 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups at the time of surgery start.
Number of subjects: 50
Study 28008704 — intervention group
Group type: EXPERIMENTAL
Intervention: Family supportive nursing care
Number of subjects: 72
Study 28008704 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 72
Study 27187056 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS applied over site A (standard motor 'hotspot')
Number of subjects: 30
Study 27187056 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS applied over site B (reorganized area)
Number of subjects: 30
Study 27187056 — intervention group
Group type: COMPARATOR
Intervention: SHAM stimulation (occipital fissure)
Number of subjects: 30
Study 27187056 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS over site B compared to site A
Number of subjects: 30
Study 27187056 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label extension study of rTMS aimed at optimized target site
Number of subjects: 30
Study 25375109 — intervention group
Group type: EXPERIMENTAL
Intervention: Curtin University's Activity, Food and Attitudes Program (CAFAP)
Number of subjects: 69
Study 22488003 — intervention group
Group type: EXPERIMENTAL
Intervention: Dressing disruption
Number of subjects: 1419
Study 20068567 — intervention group
Group type: EXPERIMENTAL
Intervention: weekly docetaxel with cisplatin and 5-fluorouracil (wTCF)
Number of subjects: 106
Study 20068567 — intervention group
Group type: EXPERIMENTAL
Intervention: weekly docetaxel with capecitabine (wTX)
Number of subjects: 106
Study 18608841 — intervention group
Group type: EXPERIMENTAL
Intervention: Model demonstrations
Number of subjects: 120
Study 18608841 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice with knowledge of performance
Number of subjects: 120
Study 18608841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of model demonstrations and practice (with and without knowledge of performance)
Number of subjects: 120
Study 18608841 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of model demonstrations and knowledge of performance practice
Number of subjects: 120
Study 18608841 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal instructions only
Number of subjects: 120
Study 18608841 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical practice without knowledge of performance
Number of subjects: 120
Study 18608841 — intervention group
Group type: EXPERIMENTAL
Intervention: Model demonstrations with physical practice without knowledge of performance
Number of subjects: 120
Study 16123681 — intervention group
Group type: EXPERIMENTAL
Intervention: peg‐interferon alpha‐2b plus ribavirin
Number of subjects: 383
Study 16123681 — intervention group
Group type: COMPARATOR
Intervention: interferon alpha‐2b plus ribavirin
Number of subjects: 383
Study 16123681 — intervention group
Group type: EXPERIMENTAL
Intervention: didanosine-containing antiretroviral regimens
Number of subjects: 383
Study 16123681 — intervention group
Group type: EXPERIMENTAL
Intervention: stavudine or nucleoside reverse transcriptase inhibitor regimens not containing didanosine
Number of subjects: 383
Study 12113586 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin for three weeks
Number of subjects: 90
Study 12113586 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-treated patients)
Number of subjects: 90
Study 10329092 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance training
Number of subjects: 80
Study 8955545 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants with high scores on the SPQ during the shadowing task.
Number of subjects: 40
Study 8955545 — intervention group
Group type: COMPARATOR
Intervention: Participants with low scores on the SPQ during the shadowing task.
Number of subjects: 40
Study 1898301 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam (20 mg)
Number of subjects: 10
Study 1898301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 6761122 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg alinidine
Number of subjects: 8
Study 6761122 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg alinidine
Number of subjects: 8
Study 6761122 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg alinidine
Number of subjects: 8
Study 6761122 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30266575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary portfolio (DP) comprising high-fibre, polyphenol-rich and vegetable-protein functional foods
Number of subjects: 81
Study 30266575 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary portfolio (DP)
Number of subjects: 81
Study 30266575 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 81
Study 29417135 — intervention group
Group type: EXPERIMENTAL
Intervention: Guselkumab, 200 mg, by subcutaneous injection at weeks 0 and 4
Number of subjects: 49
Study 29417135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 27051309 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose SFC (100 µg, two puffs daily)
Number of subjects: 40
Study 27051309 — intervention group
Group type: COMPARATOR
Intervention: High-dose fluticasone propionate (FP) alone (500 µg, daily)
Number of subjects: 40
Study 25280804 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient interdisciplinary rehabilitation programme consisting of 6 weeks of intensive physiotherapy and individual occupational therapy as needed.
Number of subjects: 0
Study 25280804 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified in the abstract.
Number of subjects: 0
Study 22366983 — intervention group
Group type: EXPERIMENTAL
Intervention: sivelestat (ELP group)
Number of subjects: 50
Study 22366983 — intervention group
Group type: COMPARATOR
Intervention: placebo (control group)
Number of subjects: 50
Study 20300683 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified maxillary oblique plate
Number of subjects: 12
Study 20300683 — intervention group
Group type: COMPARATOR
Intervention: Twin-block
Number of subjects: 12
Study 17336791 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Cravings Questionnaires‐Trait (FCQ‐T)
Number of subjects: 137
Study 17336791 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Cravings Questionnaires‐State (FCQ‐S)
Number of subjects: 137
Study 14754938 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender in a child with language delay
Number of subjects: 1600
Study 14754938 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician characteristics (female gender or being a pediatrician)
Number of subjects: 1600
Study 14754938 — intervention group
Group type: COMPARATOR
Intervention: Expression of parental concern
Number of subjects: 1600
Study 14754938 — intervention group
Group type: COMPARATOR
Intervention: Patient behaviors (disruptive vs avoidant)
Number of subjects: 1600
Study 11605556 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal vision condition
Number of subjects: 0
Study 11605556 — intervention group
Group type: COMPARATOR
Intervention: Ball‐only condition
Number of subjects: 0
Study 9678811 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine 150 mg b.d. with clarithromycin (500 mg) and amoxycillin (1000 mg) b.d. for 14 days
Number of subjects: 160
Study 9678811 — intervention group
Group type: COMPARATOR
Intervention: Nizatidine 300 mg b.d. with clarithromycin (500 mg) and amoxycillin (1000 mg) b.d. for 14 days
Number of subjects: 160
Study 7992179 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrosurgical trocars
Number of subjects: 25
Study 7992179 — intervention group
Group type: COMPARATOR
Intervention: Mechanical trocars
Number of subjects: 25